Immunohistochemical analysis of cleaved caspase-3 detects high level of apoptosis frequently in diffuse large B-cell lymphomas of the central nervous system

Pathology International

Volumn 55, Issue 3, 2005, Pages 122-129

  Arai, Momoko ^a   Sasaki, Atsushi ^a   Saito, Nobuhito ^a   Nakazato, Yoichi ^a  

^a GUNMA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Apoptosis; Bax; Caspase 3; Diffuse large B cell lymphoma; Primary central nervous system lymphoma

Indexed keywords

CASPASE 3; FAS ANTIGEN; FORMALDEHYDE; KI 67 ANTIGEN; PARAFFIN; PROTEIN BAX; PROTEIN BCL 2; PROTEIN P53; SINGLE STRANDED DNA;

ADULT; AGED; APOPTOSIS; ARTICLE; CENTRAL NERVOUS SYSTEM; CLINICAL ARTICLE; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; LARGE CELL LYMPHOMA; MALE; NICK END LABELING; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ADULT; AGED; AGED, 80 AND OVER; APOPTOSIS; BRAIN NEOPLASMS; CASPASE 3; CASPASES; COMBINED MODALITY THERAPY; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; IMMUNOENZYME TECHNIQUES; IN SITU NICK-END LABELING; KI-67 ANTIGEN; LYMPHOMA, B-CELL; LYMPHOMA, LARGE-CELL, DIFFUSE; MALE; MIDDLE AGED; TUMOR MARKERS, BIOLOGICAL;

EID: 16444381574     PISSN: 13205463     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1440-1827.2005.01808.x     Document Type: Article

References (40)

1. Eby NL, Grufferman S, Flannelly CM et al. Increasing incidence of primary brain lymphoma in the US. Cancer 1988; 62: 2461-5.
2. Ferreri AJ, Reni M, Pasini E et al. A multicenter study of treatment of primary CNS lymphoma. Neurology 2002; 58: 1513-20.
3. Paulus W, Jellinger K, Morgello S, Deckert-Schlüter M. Malignant lymphomas. In: Kleihues P, Cavenee WK, eds. World Health Organization Classification of Tumours. Pathology and Genetics of the Nervous System. Lyon: IARC Press, 2000; 198-203.
4. Cobbers JMJL, Wolter M, Reifenberger J et al. Frequent inactivation of CDKN2A and rare mutation of TP53 in PCNSL. Brain Pathol 1998; 8: 263-76.
5. Larocca LM, Capello D, Rinelli A et al. The molecular and phenotypic profile of primary central nervous system lymphoma identifies distinct categories of the disease and is consistent with histogenetic derivation from germinal center-related B cells. Blood 1998; 92: 1011-19.
6. INK4a genes in primary central nervous system lymphomas. Cancer Res 2001; 61: 6335-9.
7. Itoyama T, Sadamori N, Tsutsumi K et al. Primary central nervous system lymphomas. Immunophenotypic, virologic, and cytogenetic findings of three patients without immune defects. Cancer 1994; 73: 455-63.
8. Rickert CH, Dockhorn-Dworniczak B, Simon R et al. Chromosomal imbalances in primary lymphomas of the central nervous system. Am J Pathol 1999; 155: 1445-51.
9. Seto M. Genetic and epigenetic factors involved in B-cell lymphomagenesis. Cancer Sci 2004; 95: 704-10.
10. Deckert-Schlüter M, Rang A, Wiestler OD. Apoptosis and apoptosis-related gene products in primary non-Hodgkin's lymphoma of the central nervous system. Acta Neuropathol 1998; 96: 157-62.
11. Camilleri-Broët S, Camparo P, Mokhtari K et al. Overexpression of bcl-2, bcl-x, and bax in primary central nervous system lymphomas that occur in immunosuppressed patients. Mod Pathol 2000; 13: 158-65.
12. Taniguchi E. Primary lymphoma of the central nervous system: a clinicopathologic study. Brain Tumor Pathol 2001; 18: 101-8.
13. Konstantinidou A, Korkolopoulou P, Patsouris E et al. Apoptosis detected with monoclonal antibody to single-stranded DNA is a predictor of recurrence in intracranial meningiomas. J Neurooncol 2001; 55: 1-9.
14. Korkopoulou PA, Konstantinidou AE, Patsouris ES et al. Detection of apoptotic cells in archival tissue from diffuse astrocytomas using a monoclonal antibody to single-stranded DNA. J Pathol 2001; 193: 377-82.
15. Kumamoto H, Kimi K, Ooya K. Immunohistochemical analysis of apoptosis-related factors (Fas, Fas ligand, caspase-3 and single-stranded DNA) in ameloblastomas. J Oral Pathol Med 2001; 30: 596-602.
16. Ohshima K, Muta K, Nakashima M et al. Expression of human tumor-associated antigen RCAS1 in Reed-Sternberg cells in association with Epstein-Barr virus infection: a potential mechanism of immune evasion. Int J Cancer 2001; 93: 91-6.
17. Zhao H, Morimoto T, Sasa M et al. Immunohistochemical expression of uPA, PAI-1, cathepsin D and apoptotic cells in ductal carcinoma in situ of the breast. Breast Cancer 2002; 9: 118-26.
18. Dukers DF, Oudejans JJ, Vos W et al. Apoptosis in B-cell lymphomas and reactive lymphoid tissues always involves activation of caspase 3 as determined by a new in situ detection method. J Pathol 2002; 196: 307-15.
19. Donoghue S, Baden HS, Lauder I et al. Immunohistochemical localization of caspase-3 correlates with clinical outcome in B-cell diffuse large-cell lymphoma. Cancer Res 1999; 59: 5386-91.
20. Jaffe ES, Harris NL, Stein H, Vardiman JW, eds. World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues. Lyon: IARC Press, 2001.
21. Columbano A. Cell death: current difficulties in discriminating apoptosis from necrosis in the context of pathological processes in vivo. J Cell Biochem 1995; 58: 181-90.
22. Belloc F, Belaud-Rotureau MA, Lavignolle V et al. Flow cytometry detection of caspase 3 activation in preapoptotic leukemic cells. Cytometry 2000; 40: 151-60.
23. Alizadeh AA, Eisen MB, Davis RE et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature 2000; 403: 503-11.
24. Dogan A, Bagdi E, Munson P et al. CD10 and BCL-6 expression in paraffin sections of normal lymphoid tissue and B-cell lymphomas. Am J Surg Pathol 2000; 24: 846-52.
25. Bai M, Agnantis NJ, Skyrlas A et al. Increased expression of the bcl6 and CD10 proteins is associated with increased apoptosis and proliferation in diffuse large B-cell lymphomas. Mod Pathol 2003; 16: 471-80.
26. Ree HJ, Yang WI, Kim CW et al. Coexpression of Bcl-6 and CD10 in diffuse large B-cell lymphomas: significance of Bcl-6 expression patterns in identifying germinal center B-cell lymphoma. Hum Pathol 2001; 32: 954-62.
27. Choi JS, Nam D-H, Ko YH et al. Primary central nervous system lymphoma in Korea: comparison of B- and T-cell lymphomas. Am J Surg Pathol 2003; 27: 919-28.
28. Hannun YA. Apoptosis and the dilemma of cancer chemotherapy. Blood 1997; 89: 1845-53.
29. Kramer MHH, Hermans J, Wijburg E et al. Clinical relevance of BCL2, BCL6, and MYC rearrangements in diffuse large B-cell lymphoma. Blood 1998; 92: 3152-62.
30. Adida C, Haioun C, Gaulard P et al. Prognostic significance of survivin expression in diffuse large B-cell lymphomas. Blood 2000; 96: 1921-5.
31. Hayashi Y, Iwato M, Arakawa Y et al. Homozygous deletion of INK4a/ARF genes and overexpression of bcl-2 in relation with poor prognosis in immunocompetent patients with primary central nervous system lymphoma of the diffuse large B-cell type. J Neurooncol 2001; 55: 51-8.
32. Mancini M, Nicholson DW, Roy S et al. The caspase-3 precursor has a cytosolic and mitochondrial distribution: implications for apoptotic signaling. J Cell Biol 1998; 140: 1485-95.
33. ten Berge RL, Meijer CJ, Dukers DF et al. Expression levels apoptosis-related proteins predict clinical outcome in anaplastic large cell lymphoma. Blood 2002; 99: 4540-46.
34. Dukers DF, Meijer CJ, ten Berge RL et al. High numbers of active caspase-3-positive Reed-Sternberg cells in pretreatment biopsy specimens of patients with Hodgkin disease predict favorable clinical outcome. Blood 2002; 100: 31-42.
35. Kaufmann SH, Hengartner MO. Programmed cell death: alive and well in the new millennium. Trends Cell Biol 2001; 11: 526-34.
36. Rossi D, Gadiano G. Messengers of cell death: apoptotic signaling in health and disease. Hematologica 2003; 88: 212-18.
37. Baiocchi RA, Khatri VP, Lindemann MJ et al. Phenotypic and functional analysis of Fas (CD95) expression in primary central nervous system lymphoma of patients with aquired immunodeficiency syndrome. Blood 1997; 90: 1737-46.
38. Christov C, Adle-Biassette H, Lechapt E et al. Primary brain lymphoma cell turnover differs in patients with and without AIDS: relationships to bcl-2 expression and host cell reaction. J Neuropathol Exp Neurol 1999; 58: 1069-77.
39. Weller M. Glucocorticoid treatment of primary CNS lymphoma. J Neurooncol 1999; 43: 237-9.
40. Geley S, Hartmann BL, Kapelari K et al. The interleukin-1β- converting enzyme inhibitor CrmA prevents APO-1/Fas but not glucocorticoid- induced poly (ADP-ribose) polymerase cleavage and apoptosis in lymphoblastic leukemia cells. FEBS Lett 1997; 402: 36-40.